Kelun-Biotech Presents Pivotal Phase II Data for Lunbotinib Fumarate (A400/EP0031) in RET Fusion-Positive NSCLC at 2026 ASCO

About this update from Sichuan Kelun-biotech Biopharmaceutical Co., Ltd. Class H

[{"type":"text","content":"CHENGDU, China, May 29, 2026 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company", 6990.HK) announced that at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting held in Chicago, USA, results from the pivotal Phase II study of the Company's next-generation selective RET inhibitor, lunbotinib fumarate (A400/EP0031, 宁泰莱®[1]), in advanced rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC) were presented as an oral report by Professor Qing Zhou from Guangdong Provincial People's Hospital (Abstract #8505, Lung Cancer—Metastatic Non-Small Cell). Based on these results, a New Drug Application (NDA) for lunbotinib fumarate for the treatment of adult patients with locally advanced or metastatic RET fusion-positive NSCLC has been accepted by the National Medical Products Administration (NMPA) of China.","length":903,"tagName":"p"},{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":300,"url":"https://media.zenfs.com/en/prnewswire.com/78e78aa81f8d9cc5ab6dd5af5477a83e"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/nA1Xdc0Cc4.KfW7XG4c9fw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTUyOQ--/https://media.zenfs.com/en/prnewswire.com/78e78aa81f8d9cc5ab6dd5af5477a83e","width":400,"height":300},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/S_gW4dHcmyoUeFdrOMQ4ww--/YXBwaWQ9aGlnaGxhbmRlcjt3PTY0MDtoPTQ4MA--/https://media.zenfs.com/en/prnewswire.com/78e78aa81f8d9cc5ab6dd5af5477a83e","width":400,"height":300}},"href":"https://mma.prnewswire.com/media/2991270/image1.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"The study enrolled 71 patients who had previously received platinum-based chemotherapy and immunotherapy (pre-treated patients) and 92 patients who had not received prior systemic therapy (treatment-naïve patients). As of the data cutoff date of October 29, 2025, the median follow-up was 22.6 months and 20.7 months, respectively.","length":331,"tagName":"p"},{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":223,"url":"https://media.zenfs.com/en/prnewswire.com/755a42cca3979020f412601278cb31df"},"resized":{"url":"htt...

More updates from Sichuan Kelun-biotech Biopharmaceutical Co., Ltd. Class H